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Abstract
Aim: The study objective was to examine the association of hypertension in the Lebanese population with three renin–
angiotensin system gene polymorphisms (RAS): angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and 
angiotensin-receptor type 1 (AT1R).
Methods: A total of 270 subjects (124 hypertensive vs 146 normotensive) were genotyped for ACE insertion (I)/deletion 
(D), AGT (M235T), and AT1R (A1166C) gene polymorphisms by polymerase chain reaction and restriction fragment 
length polymorphism.
Results: The studied genes showed no deviation from Hardy–Weinberg equilibrium. No association could be reported 
with the ACE I/D polymorphism, although the D allele frequency was high (77%) in patients. AGT TT genotype prevalence 
was found to be lower in hypertensive versus normotensive subjects (p < 0.0001). AT1R CC and AC genotypes were 
significantly more frequent in hypertensive than normotensive subjects (p < 0.0001).
Conclusion: The first conducted study on the RAS gene polymorphisms in Lebanese hypertensive patients demonstrated 
a possible association of the AGT T and AT1R C alleles with hypertension.
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Introduction
Hypertension (HTN), or high blood pressure (BP), is the 
most common risk factor for myocardial infarction,1 stroke, 
end-stage renal disease and peripheral vascular diseases.2 
HTN is present in approximately two-thirds of all persons 
over the age 65 years. Although ageing, obesity and envi-
ronmental factors such as alcohol consumption3 contribute 
to the onset of HTN, genetic factors also determine a sub-
stantial proportion of the variance of BP in the general pop-
ulation.1 The renin–angiotensin system (RAS) is an 
important system of BP control through its effect on vascu-
lar tone, renal haemodynamics and sodium and volume 
homeostasis. Several studies have established that the RAS, 
including the angiotensin-converting enzyme (ACE) inser-
tion (I)/deletion (D), the angiotensinogen (AGT) M235T 
and the angiotensin-receptor type 1 (AT1R) A1166C genetic 
polymorphisms have all been implicated in the pathogene-
sis of essential HTN.4,5
RAS gene associations with high BP have been reported 
across various populations and ethnic groups. A high preva-
lence of the D allele and/or DD genotype has been shown in 
hypertensive subjects throughout the world.5–15 The AGT 
TT genotype has been associated with HTN similarly across 
a wide range of populations. Numerous studies have also 
demonstrated an association between the AT1R A1166C 
SNP polymorphism and essential HTN.16–22 However, some 
of the evidence identifying associations between HTN and 
the RAS gene polymorphisms has been conflicting. For 
example, several studies have reported no association with 
the ACE I/D,23–27 the AGT M235T28–30 or the AT1R A1166C 
polymorphisms.31–33 It has been suggested that this incon-
sistency could be due to variation in genetic and environ-
mental backgrounds across the numerous populations.34
Previous studies identified some populations of the 
Middle East as having lower frequencies of the ACE 
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insertion, this being indicative of ancient populations; the 
ancestral state of the Alu repeat being the D allele.35–39 
Lebanon is a small country of 10,452 km2 on the eastern 
shores of the Mediterranean Sea, with a population of 
approximately 4 million people, with a worldwide diaspora 
estimated at 15 million. The fact that the Lebanese popula-
tion had such a low frequency of the I allele, then, is also 
considered to be indicative of this population being ances-
tral, with regards to human demographic history. The prev-
alence of HTN among the Lebanese is estimated at 23.1%, 
and up to the date of the present study there has been no 
information on RAS gene polymorphisms among Lebanese 
hypertensive patients. Given the nature of ACE I/D poly-
morphism in the Middle Eastern populations, it seems 
appropriate to question the health consequences of a poly-
morphism closely associated with the RAS. Specifically, 
does the high frequency of the D allele correspond with 
hypertension in a population where the DD genotype is pre-
dominant? Less information is available on the global 
trends of the AGT and A1166C polymorphisms, which are 
also implicated in hypertension, so predictions are difficult 
to make with regards to these two markers. Thus, this study 
aimed at investigating the association between genetic pol-
ymorphisms at three RAS genes (ACE, AGT, and AT1R) 
and BP in a population-based sample from Lebanon.
Materials and methods
Study sample
Hypertensive patients. The patient sample (age 29–85; 
onset HTN < 60 years; otherwise healthy) collection took 
place in 10 different community pharmacies located in dif-
ferent areas of Lebanon. All records of adult male and 
female patients taking antihypertensive drugs and/or 
patients with systolic BP ≥ 140 and/or diastolic BP ≥ 90 
were selected. One-hundred and twenty-four samples were 
collected (61:63 male:female), mean age of sample = 63 
years (SD = 14 years).
Normotensive individuals. The control sample was chosen 
as for the patient sample except that the individuals had 
never been treated with medication for HTN and their 
systolic and diastolic BPs were < 140 and < 90 mmHg 
respectively. One-hundred and forty-six samples were col-
lected (69:77 male:female), mean age of sample = 27 years 
(SD = 9 years). All subjects agreed to participate in the 
study after full explanation of what was involved, and the 
project was approved by the School of Pharmacy Research 
Committee.
Genomic protocols
Sample collection and DNA extraction. Each subject pro-
vided a cheek swab for DNA extraction. The presence of 
the insertion/deletion allele in intron 16 of the ACE gene 
was detected using the method of Rigat et al40 with some 
modifications.41 The I and D alleles were manifest as 490 
bp and 190 bp bands respectively. Because of the possibil-
ity of preferential amplification of the D fragment in rela-
tion to the I fragment, resulting in mistyping of I/D as the 
DD genotype, all DD genotypes were reconfirmed42 in 
additional gels.
AGT (M235T) and AT1R (A1166C) polymorphism genotyping. 
Polymerase chain reaction and restriction fragment length 
polymorphism (RFLP) based protocols were used to iden-
tify the AGT43 and AT1R
44 gene polymorphisms. The 
homozygous M235T was represented as 164 bp. Both 164 
bp and 140 bp fragments were apparent for heterozygotes. 
TT homozygotes were identified as a single band of 140 bp. 
The AT1R CC genotype gives two bands of 224 bp and 143 
bp, and the heterozygous AC genotype as three bands of 
367 bp, 224 bp and 143 bp. The AA genotype presents a 
single band of 367 bp.
Statistical analysis
Age, sex, weight, height, body mass index (BMI) and 
ACE, AGT and AT1R genotypes were tabulated for hypo-
tensive and normotensive individuals. The association 
between ACE, AGT and AT1R genotypes with the risk of 
hypertension was estimated by computing odds ratios 
(OR). We also adopted a generalised linear modelling 
(GLM) approach for hypertension with fixed effects, 
implemented in R (R: A Language and Environment for 
Statistical Computing, R Development Core Team, 
www.R-project.org). Binomial error distributions were 
assumed and logistic regression used to select the best-
fitting minimal adequate model.45,46 This regression 
approach also allows control of confounding variables.47 
The significance level of all tests was set at 0.05.
Results
The genotype frequencies of each of the three genes were 
in Hardy–Weinberg equilibrium, both in the total sample 
group and segregated into hypertensive and normoten-
sive groups. Genotype and allele frequency comparisons 
between hypertensive and normotensive groups are pre-
sented in Table 1. Odds ratios for each of the three mark-
ers for both full and reduced datasets are presented in 
Table 2.
Using the full dataset, the minimum adequate model for 
hypertension explained 52.13% of the total variation, with 
an Akaike Information Criterion (AIC) score of 73.33 (Table 
3(a)). Importantly, 69% of the total deviance is explained 
by age. Weight and height are weakly correlated with age 
(R2 = 0.035 and 0.126 respectively) and are significant 
effects. The AT1 genotype also has a significant effect on 
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hypertension. However, it is fully expected that hyperten-
sion should correlate with age and the mean ages of the 
hypertensive and normotensive groups are significantly dif-
ferent (t205 = 24.7, p < 0.001). When age is removed from 
the model the minimum adequate model for hypertension 
explains 73.9% of the deviance, but with an AIC score of 
188.45 (Table 3(b)). Interestingly, AT1, AGT and ACE now 
all have significant effects.
Table 1. Genotype/allele frequency comparison of the ACE I/D, AGT M235T and AT1R A1166C genes among hypertensive and 
normotensive subjects
Gene ACE (I/D) AGT (M235T) AT1R (A1166C)
Genotype II ID DD MM MT TT AA AC CC
Hypertensive 
N = 124
(%)
9
(7)
37
(30)
78
(63)
34
(27)
72
(58)
18
(15)
31
(25)
64
(52)
29
(23)
Normotensive
N = 146
(%)
12
(8)
58
(40)
76
(52)
38
(26)
59
(40)
49
(34)
83
(57)
52
(36)
11
(7)
p 0.015 < 0.0001 < 0.0001
Allele I D M T A C
Hypertensive 0.22 0.78 0.56 0.44 0.51 0.49
Normotensive 0.28 0.72 0.46 0.54 0.75 0.25
p < 0.01 < 0.0001 < 0.0001
p values derived from c2 analyses.
A: adenine, ACE: angiotensin converting enzyme, AGT: angiotensinogen, AT1R: angiotensin receptor subtype 1, C: cytosine, D: deletion, I: insertion, 
M: methionine, N: number, T: threonine.
Table 2. Table of odds ratios (N = 270)
Gene Odds ratio p 95% CI N
AT1 3.952 < 0.001 2.345 to 6.661 270
AGT 2.975 < 0.001 1.622 to 5.455 270
ACE 1.562 < 0.1 0.959 to 2.544 270
Table 3(a). Summary of minimum adequate model of hypertension (binomial response, N = 270) 
Fixed effects d. f. Parameter estimate (SE) % deviance explained p
Age 1  0.202 (0.038) 121.79 < 0.0001
Weight 1 –1.118 (0.623)  33.026 < 0.0001
Height 1 –0.955 (0.315)  26.187 < 0.0001
AT1 2   7.064    0.029
Weight: Height 1  0.008 (0.004)   6.106    0.013
Total deviance explained by the main effects and first order interactions = 50.49%. For each term, the deviance explained refers to the change in 
deviance attributed to the term in question when fitted last, as a proportion of total deviance explained by the main effects in the minimum adequate 
model. p values were estimated by comparison with the reduced model not containing the term in question.
Table 3(b). Summary of minimum adequate model of hypertension (binomial response, N = 270) with age removed from the 
model
Fixed effects d.f. Parameter estimate (SE) % deviance explained p
Height 1 –0.358 (0.047) 126.53 < 0.0001
Weight 1  0.212 (0.03) 116.22 < 0.0001
AT1 2  15.835    0.0004
AGT 2   8.823    0.012
ACE 2   7.883    0.019
Total deviance explained by the main effects = 73.9%.
 at Lebanese American University on September 26, 2016jra.sagepub.comDownloaded from 
4 Journal of the Renin-Angiotensin-Aldosterone System XX(X)
Discussion
Conflicting results are found in the literature on the rela-
tionship between HTN and the RAS gene polymorphisms, 
i.e. ACE I/D, AGT M235T and AT1R A1166C. This study 
aimed at determining the polymorphism of the RAS genes 
based on a population study in order to contribute to the 
current debate by examining a specific population at the 
extreme end of the frequency range for the ACE polymor-
phisms. The initial study hypothesis was that polymor-
phisms associated with increased RAS activity may 
predispose to HTN, whereas those that decrease RAS activ-
ity might offer some protection. For example, it might be 
expected that the AGT T allele, which is associated with 
markedly higher plasma AGT,48 the ACE D allele, which is 
associated with greater ACE activity,40 and the AT1R C 
allele, which is associated with greater responses to angi-
otensin II at lower concentrations,49 might all be more prev-
alent within a hypertensive population.
Generally, ACE D allele was at a higher prevalence in the 
Lebanese (72%) relative to Caucasian populations (typically 
~56%), African (~60%) and Asian populations (~39%).34 
Specifically, for the ACE I/D polymorphism, our results 
showed a significant difference between hypertensive and 
normotensive groups across genotypes (p < 0.05), although 
the OR for the DD genotype was not significant (p = 0.08). 
These results are not quite in agreement with previously 
published ACE–HTN linkage and association studies.26 The 
D allele frequency was significantly different between the 
hypertensive and normotensive groups (c2, p < 0.01), but 
again the OR was not significant (OR 1.370, p = 0.136).
AGT 235T allele was found to have a frequency of 49%, 
which is higher than the published frequency of 42% in 
Caucasian but lower than the 77% in African and Asian 
populations.34 The genotype frequencies differed signifi-
cantly between the two groups and the OR 2.97 was signifi-
cant (p < 0.001). Jeunemaitre and associates4 were the first 
to report the linkage of the molecular variants M235T with 
HTN in Caucasian populations. Again, there has been some 
inconsistency, with some studies in support of this find-
ing,18 whereas others were not.50 Positive findings from 
previous studies have reported the involvement of the T 
allele, whereas, here, we found that the MM/MT genotypes 
increased the risk of hypertension. Thus, this study pro-
vides no evidence in support of the initial hypothesis that 
the T allele is associated with higher risk of HTN.
As for AT1R polymorphisms, the frequency of the C 
allele in the Lebanese is 36%, which compares well with 
general Caucasian populations being at around 35%, but 
differs markedly from Asian populations, where it is around 
5% (NCBI database). The genotypes differ significantly 
between hypertensive and normotensive subjects (c2, 
p < 0.001) and the CC/AC genotypes give a significant OR 
3.95 (p < 0.001). Since its first description, little progress 
has been made in unravelling the functional significance of 
AT1R polymorphism with respect to diseases, although the 
AT1 receptor mediates most of the known physiological 
effects of angiotensin II. In agreement with this study, AT1R 
CC and/or AC genotypes have shown a significant interac-
tion with the disease phenotype in previous studies. Such a 
finding supports the initial hypothesis that increased RAS 
activity predisposes to hypertension in that the CC variant 
of the AT1R (A1166C) polymorphism has previously been 
seen to be associated with increased responsiveness to 
angiotensin II.49
With a sample size of N = 270, a simple c2 goodness-of-
fit test for association has sufficient power (1-b = 0.8; 
a = 0.05),51 should the effect size be greater than w = 0.17, 
which is considered to be somewhere between a small to 
medium effect size. Given this is the case, we would have 
to conclude that there is not a small to medium effect size 
for the ACE polymorphism. Hence, in order to determine 
whether the ACE polymorphism plays any role in influenc-
ing hypertension, a larger study is required.
The opportunistic design of this study resulted in the 
hypertensive and normotensive groups being age-stratified, 
which generated an obvious flaw in that a proportion of the 
younger, currently normotensive individuals may go on to 
develop HTN. Regression analyses identified that age alone 
explains 69.4% of the deviance. Weight and height are 
weakly correlated with age in these datasets (R2 = 0.036 and 
0.126 respectively). A more involved model including all 
the other significant terms is given in Table 3(a). Although 
this model shows weight, height and AT1 to also be signifi-
cant, this model does in fact explain less of the total devi-
ance (50.49%) than the age-alone model. When age is 
removed as a main effect, weight, height and the three 
markers generate a model that explains 73.9% of the total 
deviance (Table 3(b)). Weight and height are relatively 
weakly correlated (R2 = 0.27), but models with one of these 
two terms removed are inferior, explaining around 21% of 
the total deviance. Interestingly, BMI did not remain as a 
significant factor in any of the models. It is difficult to 
explain why height and weight remain as influential fac-
tors. Each marker appears to explain small, but significant 
proportions of the deviance. In some respects, this is to be 
expected as very few association studies of complex traits 
identify markers of large effect size. The genotypes explain 
around 2% of the deviance, which is significant but proba-
bly not biologically meaningful. Associations are typically 
reported giving OR. However, Table 2 shows that no signifi-
cant OR is identified for ACE. The underlying rationale for 
each of these two approaches to identifying the influence of 
genotypes on HTN is quite different, hence the results are 
not directly comparable; indeed the interpretation of OR is 
not always straightforward.52 If anything, this study has 
illustrated how markers that appear to have a large influ-
ence using OR may actually be responsible for very little of 
the total variation in a given phenotype. Nevertheless, it 
does appear that each of these three markers warrant further 
investigation as regards their influence of HTN.
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This RAS gene polymorphisms study has shown incon-
sistencies with respect to other previous population studies 
on HTN. Whether these differences represent the historic 
multi-ethnic origin of the Lebanese population remains to 
be resolved; certainly the variation in allele frequencies 
between Lebanese and other broad ethnic groups (e.g. 
Caucasian, Asian and African) suggests that this could be 
the case.39
Conclusion
Of the demographic factors studied, weight and height of 
the individual contributed to the greatest proportion of vari-
ation in HTN in the study populations, despite these being 
only weakly correlated with the age of the subjects. Logistic 
regression analysis identified a small, but significant influ-
ence of AT1, AGT and ACE on HTN. When age is control-
led for, AGT has the greatest influence. OR analysis also 
suggests that AT1 plays a significant role.
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